Biogen, Alkermes Sue Teva to Block Copies of Vumerity MS Drug

Biogen and Alkermes said Teva’s proposed generic version of Vumerity infringes three patents for the multiple sclerosis drug that Alkermes licenses exclusively to Biogen.

• Biogen and Alkermes are seeking a court order blocking copies until the patents have expired, according to complaint filed Wednesday in federal court in Wilmington, Delaware
• Patents cover drug’s active ingredient, diroximel fumarate, and its use in treating MS, and expire in September 2033: FDA Orange Book
• Sales of Vumerity improved in the fourth quarter of 2020, but Bloomberg Intelligence analyst Jenna Li wrote in a Feb. 11 note that Biogen’s “ability to make up ...